Pre-Open Stock Movers 04/09: (NLS) (BIG) (DIS) Higher; (TTOO) (COST) (SBUX) Lower (more...)

Pre-Open Stock Movers

Tiziana Life Sciences plc (Nasdaq: TLSA) 73.7% HIGHER; announced today that it has developed investigational new technology to treat COVID-19 infections, which consists of direct delivery of anti-IL-6 receptor (anti-IL-6R) monoclonal antibodies (mAbs) into the lungs using a handheld inhaler or nebulizer. Development of this novel technology is a step forward toward expediting development of TZLS-501, a fully-human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody (mAb) for treatment of patients infected with COVID-19 (SARS-CoV-2) coronavirus. The Company believes the technology could also be applicable for use with other FDA approved mAbs and drugs. The Company has submitted a provisional patent application for the delivery technology.

Nautilus, Inc. (NYSE: NLS) 39% HIGHER; reported preliminary first quarter 2020 sales results and offered a brief business update given the unprecedented environment related to the coronavirus disease 2019 (COVID-19). Preliminary net sales for the first quarter of 2020 were approximately $94 million, up 11% versus the same quarter in 2019, the first time quarterly sales have grown year-over-year since Q3, 2018. This increase was driven by the power of the Bowflex and Schwinn brands, recent strategic and operational changes, disciplined execution, and a near-term trend toward home fitness.

Helix Energy Solutions Group, Inc. (NYSE: HLX) 20.6% HIGHER; adds to 25% intra-day gain.

Mesoblast Limited (Nasdaq: MESO) 20% HIGHER; announced that its allogeneic mesenchymal stem cell (MSC) product candidate remestemcel-L will be formally evaluated in a randomized, placebo-controlled trial in 240 patients with acute respiratory distress syndrome (ARDS) caused by coronavirus infection (COVID-19). This multi-center Phase 2/3 trial will be conducted as a public-private partnership in a collaboration with the Cardiothoracic Surgical Trials Network (CTSN), which was established by the United States National Institutes of Healths National Heart, Lung and Blood Institute (NHLBI) as a flexible platform for conducting collaborative trials. Mesoblast holds an Investigational New Drug (IND) Application from the United States Food and Drug Administration (FDA) for use of remestemcel-L in the treatment of patients with COVID-19 ARDS, and will provide investigational product for the trial.

iBio, Inc. (NYSE: IBIO) 18% HIGHER; announced the signing of two Master Services Agreements (the MSAs) and a Memorandum of Understanding (the MoU) with the Infectious Disease Research Institute (IDRI) in support of iBios SARS-CoV-2 Virus-Like Particle (VLP) vaccine development.

Big Lots, Inc. (NYSE: BIG) 18% HIGHER; announced that it has entered into sale and leaseback agreements with affiliates of Oak Street Real Estate Capital, LLC ("Oak Street") relating to the company's distribution centers in Columbus, OH, Durant, OK, Montgomery, AL, and Tremont, PA. The transactions are expected to close in the company's fiscal second quarter, subject to continued due diligence, final documentation, and other customary closing conditions.

T2 Biosystems (NASDAQ: TTOO) 11.7% LOWER; to offer up to $95 million in common stock.

Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) 8.3% HIGHER; Vanda and the University of Illinois at Chicago (UIC) today announced a research partnership focused on the investigation of small molecules with the potential to treat COVID-19. The collaboration will include the use of a high-throughput screening assay to identify small molecules that may prevent cathepsin-L cleavage of SARS-CoV-2 (COVID-19) glycoproteins that are required for viral processing in the host cell.

Intelsat S.A. (NYSE: I) 6.7% HIGHER; adds to intra-day 57% gain

Disney+ (NYSE: DIS) 5% HIGHER; Disney+ has now achieved another new milestone, with 50 million paid subscribers globally within five months after its U.S. launch.

Costco (NASDAQ: COST) 3.1% LOWER; Total March Comps Increase 9.6%; E-Commerce Up 48.3%

Starbucks Corp (NASDAQ: SBUX) 2.2% LOWER; withdraws guidance for fiscal 2020, suspends buyback plan

You May Also Be Interested In

• Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
• AstraZeneca (AZN) Announces Voydeya Approval in EU as add-on to ravulizumab or eculizumab
• Snap (SNAP), Meta (META) gain as House orders sale or ban of TikTok